Research programme: herpes simplex virus type 2 vaccines - Genocea Biosciences

Drug Profile

Research programme: herpes simplex virus type 2 vaccines - Genocea Biosciences

Alternative Names: GEN-002; HSV-2 prophylactic (Px) vaccine - Genocea Biosciences; HSV-2 Px; ICP4383-766 + gD2; ICP4383-766 + TMR341-363; ICP4383-766 and gD2

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fred Hutchinson Cancer Research Center; Genocea Biosciences; University of Washington
  • Developer Genocea Biosciences
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Herpes simplex virus type 2 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in USA (Parenteral)
  • 06 May 2015 Genocea plans to file an IND application for Herpes simplex virus infections (Genocea Biosciences 10-K, May 2015)
  • 05 Dec 2013 Preclinical development of a prophylactic HSV-2 vaccine is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top